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Biologic agents have becomemore common to treat patients with psoriasis, but concerns about their effect
on pregnancy and lactation often preclude this treatment during these time periods. During the past
decade, we have gained a much better understanding of the course of psoriasis during pregnancy and
the safety of the use of biologic agents during pregnancy and lactation. Under certain circumstances,
biologic agents can be considered appropriate treatment options for patientswho are pregnant or lactating.
© 2016Women's Dermatologic Society. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Psoriasis is a chronic, immune-mediated inﬂammatory disorder.
Psoriasis prevalence rates are estimated between 1.5% and 2%world-
wide, and more than 7.2 million people are affected in the United
States alone (Jacobson et al., 2011; Rachakonda et al., 2014). The av-
erage age of female patients at the time of disease onset is 28 years,
which means that many of these patients with psoriasis are of child-
bearing potential (Tauscher et al., 2002).
Over the past decade, we have seen the emergence of biologic
agents as a mainstay of treatment for patients with psoriasis. In
2013, approximately 25% of patients with psoriasis were treated
with biologic agents and primarily with tumor necrosis factor-alpha
(TNF-alpha) inhibitors such as adalimumab and etanercept
(Armstrong et al., 2013). Today, newer and even more effective bio-
logic therapieswithmore targetedmechanisms of action are available
to patients. Thus, it is expected that most dermatologists will encoun-
ter female patients with psoriasis who are pregnant or desire to be-
come pregnant while treated with a biologic agent. Data on this
subject are limited but expanding, and dermatologists who have an
understanding of the clinical course of psoriasis and the impact of bi-
ologic agents during pregnancy will be better equipped to weigh the
risks and beneﬁts of treatment and counsel patients appropriately.
Psoriasis and pregnancy
Pregnancy is marked by complex maternal hormonal and im-
mune system changes. During pregnancy, the maternal immune sys-
tem shifts from a T helper (Th) cell 1 to a Th2 response. With this
shift, certain Th2-mediated diseases such as lupus erythematosus
worsen during pregnancy (Ruiz et al., 2014). Other T cell subsets
that are related to autoimmunediseases include Th17 and T regulato-
ry (Treg) cells. A recent review article found a greater ratio of Th17 to
Treg cells in patients with pregnancy complications and autoimmune
diseases and a reversal of this ratio in patients who had a successful
pregnancy with a tolerance to self-antigens (Figueiredo and
Schumacher, 2016).
Psoriasis is thought to be a primarily Th17-mediated disease with
some Th1 involvement and since both of these cells are downregulat-
ed during pregnancy, a patient’s disease status can ameliorate during
pregnancy. Psoriasis tends to improve for approximately half of pa-
tients, but an equal number of patients report no change or worsen-
ing of their psoriasis during pregnancy (Bobotsis et al., 2016; Murase
et al., 2005). Additionally, the majority of patients with psoriasis
report immediate postpartum disease ﬂares (Murase et al., 2005).
Psoriasis comorbidities such as diabetes, metabolic syndrome,
cardiovascular disease, and depression may also increase the risk of
negative birth outcomes. A prospective cohort study of pregnant
women with psoriasis compared with pregnant women who had
no autoimmune disease found that patients with psoriasis were
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more likely to smoke during the ﬁrst trimester of pregnancy, be
overweight or obese, and have a diagnosis of depression. These pa-
tients were also less likely to use prenatal vitamins or folate supple-
mentation at the time of conception, and such modiﬁable risk
factors could increase the risk for adverse birth outcomes (Bandoli
et al., 2010).
Pregnancy outcomes are generally poorer in patients with psoria-
sis. One study that was presented in 2012 at the European Academy
of Dermatology and Venereology found that women aged 35 years
and older with psoriasis had signiﬁcantly lower pregnancy rates
and live birth rates compared with disease-free control patients
(Powers, 2012). Studies that analyzed pregnancy in patients with
psoriasis have presented conﬂicting data with regard to poor preg-
nancy outcomes such as preterm birth, low birth weight, recurrent
miscarriage, and increased cesarean delivery, with some studies
supporting and others refuting these ﬁndings (Ben-David et al.,
2008; Lima et al., 2012; Yang et al., 2011). However, a recent review
of psoriasis and adverse pregnancy outcomes concluded that more
recent literature suggested a link between psoriasis disease severity,
pregnancy, and the development of adverse outcomes. The authors
postulated that immune system dysregulation in psoriasis likely
leads to poorer outcomes in pregnancy (Bobotsis et al., 2016).
Fetal exposure to biologic agents during pregnancy
Exposure of the fetus to biologic agents during pregnancy de-
pends on the transport across the placenta. Immunoglobulin G
(IgG) is the only major class of antibody that is transported across
the human placenta. Fetal levels of IgG in umbilical venous blood
are low in the ﬁrst two trimesters of pregnancy and do not surpass
maternal levels of IgG until the beginning of the third trimester
when active transport of the IgG molecules across the placenta in-
creases rapidly (Chambers and Johnson, 2012). Transport of IgG is fa-
cilitated by the neonatal Fc receptor (FcRn) on the placenta. Of the
four subclasses of IgG (G1-G4), IgG1 is the most effectively
transported followed by IgG4, IgG3, and IgG2, respectively
(Wakeﬁeld et al., 2011). Adalimumab and inﬂiximab are both IgG1
immunoglobulins. A prospective study of 80 patients with inﬂamma-
tory bowel disease (IBD) who were treated with adalimumab and
inﬂiximab found an inverse correlation between time of last expo-
sure to drug during pregnancy and umbilical drug concentrations in
the infant (Julsgaard et al., 2016). Etanercept is a fusion protein that
also contains an IgG1 Fcportion butwith less transplacental transport
than adalimumab or inﬂiximab (Kurizky et al., 2015).
Certolizumab differs from other biologic agents because it is a
pegylated antigen-binding fragment (Fab) antibody that lacks an Fc
region. Without this Fc region, it cannot be actively transported by
the FcRn receptor on the placenta and thus, results in minimal pla-
cental transmission (Wakeﬁeld et al., 2011). A case series of 13 pa-
tients with rheumatic disease who were treated with certolizumab
during late pregnancy showed measurements of certolizumab in
the cord blood between undetectable and 1 μg/ml comparedwith av-
erage maternal plasma levels of approximately 33 μg/ml (Förger
et al., 2016). This suggests that certolizumab may be used as a treat-
ment during late gestation without potential exposure to the new-
born. Of note, certolizumab is only approved by the U.S. Food and
Drug Administration (FDA) for the treatment of psoriatic arthritis
but results from randomized, controlled Phase II studies have
shown very good efﬁcacy in patients with psoriasis (Reich et al.,
2012).
This information is clinically signiﬁcant for both the mother and
fetus. Ideally, patients would discontinue treatment with biologic
medications prior to planned pregnancies but for many patients
with psoriasis, this situation is impractical and may not be necessary
(Horn et al., 2009). Because of the minimal placental transport of
maternal antibodies during the ﬁrst two trimesters of pregnancy,
treatment of patients with anti-tumor necrosis factor (TNF) alpha bi-
ologic medications is generally considered safe during the ﬁrst half of
pregnancy (Förger and Villiger, 2016). Recommendations for the use
of anti-TNF therapy in the treatment of patientswith IBD endorse dis-
continuation of TNF-alpha inhibitors atweek 22-24 of pregnancy, but
the rheumatology literature suggests safely continuing therapy up
until Week 30 of pregnancy (Levy et al., 2016; van der Woude and
Kanis, 2016). Newer consensus statements from the CanadianAssoci-
ation of Gastroenterology that were published in March 2016 state
that women with a low-risk of IBD relapse and a compelling reason
to discontinue treatment with anti-TNF therapy should stop at
Weeks 22 to 24 but all other women with IBD who are treated with
anti-TNF therapy are recommended to continue anti-TNF treatment
throughout the pregnancy (Nguyen et al., 2016). These recommenda-
tions were classiﬁed as a “strong recommendation” on the basis of
low-quality evidence but the assumption was that the risks of treat-
ment with anti-TNF therapy outweighed the risk of an IBD relapse
with subsequent effects on both the mother and fetus during
pregnancy.
Patients with psoriasis who continue treatment with biologic
agents during their pregnancy and particularly into the third trimes-
ter should be informed of the potential for an impaired immune re-
sponse in their newborn infants. One case report of a death due to
disseminated Bacillus Calmette-Guérin (BCG) infection following
live BCG vaccination in an infant borne to a mother receiving
inﬂiximab during pregnancy, caused signiﬁcant and warranted
alarm (Cheent et al., 2010). Multiple studies have documented that
levels of anti-TNF agents are detected in infants at birth and decline
thereafter (Chambers and Johnson, 2012); however, a few studies
noted that drug clearance could take up to 1 year after birth
(Julsgaard et al., 2016). Inﬂiximab clears more slowly than
adalimumab (Julsgaard et al., 2016). Therefore, the administration
of live vaccinations should be avoided in newborns with exposure
to TNF-alpha agents for at least 6 months after delivery but inactive
vaccinations can follow the standard schedule as recommended by
the Centers for Disease Control and Prevention (CDC).
General safety of biologic agents during pregnancy
Most of the data on biologic agents and pregnancy come from the
gastroenterology and rheumatology literature because TNF-alpha in-
hibitors aremost commonly used to treat patientswith IBD and rheu-
matoid arthritis. Because pregnant women are commonly excluded
from clinical trials, large, controlled studies of TNF-alpha inhibitors
and newer biologic agents, such as ustekinumab (IL-12/23 inhibitor),
secukinumab (IL-17 inhibitor), and ixekizumab (IL-17 inhibitor), are
lacking. Most of our limited observations come from data from ani-
mals, case reports or case series, small retrospective studies, and,
most recently, surveillance registries that collect outcomes from
pregnant patients who are treated with biologic agents. However,
these registries are subject to bias because those who experience
anomalies or adverse outcomes may be more likely to report such
events.
Investigations into the role of TNF-alpha in embryogenesis in TNF-
alpha knockout mice showed that TNF-alpha may play a role in the
prevention of structural anomalies by either activating defense
mechanisms that protect the embryo from harmful maternal stimuli
or stresses or signaling for apoptosis if overwhelming detrimental
signals occur (Toder et al., 2003).
In contrast, concern about the increased risk of congenital
malformations, preterm birth, low birth weight, and spontaneous
abortions have been raised about treatment with TNF-alpha inhibi-
tors. For reference, according to the FDA, the risk ofmajor birth defect
is 2% to 4% and the rate ofmiscarriage is 15% to 20% in theU.S. general
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population. Carter et al. (2006) originally published a case report and
described an infant who was born with vertebral, anal, tracheal,
esophageal, and radius or renal (VATER) association to a mother
whowas treatedwith etanercept. In 2009, the same author published
another article that proposed a causal relationship between TNF-
alpha inhibition and VATER association on the basis of a review of
the FDA database of birth defects that were reported in mothers
who were treated with TNF-alpha inhibitors (Carter et al., 2009).
The methodology was controversial at the time, and further evalua-
tion of larger registries failed to conﬁrm this association (Koren and
Inoue, 2009; Verstappen et al., 2011).
Still, conﬂicting data have been published about the general safety
of biologic agents in pregnancy. A prospective, observational, multi-
center cohort study that was conducted within the European Net-
work of Teratology Information between 1993 and 2013 compared
495 pregnancies during which the patients were exposed to TNF-
alpha inhibitors (adalimumab, certolizumab, etanercept, golimumab,
and inﬂiximab) with 1532 control subjects. The study concluded that
those patients whowere exposed to TNF-alpha inhibitors had amod-
erately increased risk of birth defects (of which no pattern could be
ascertained), an increased risk of preterm birth and low birth weight,
and no increased risk of spontaneous abortion (Weber-Schoendorfer
et al., 2015). Unfortunately, the control subjects did not have disease,
and, therefore, the authors could not attribute these ﬁndings to dis-
ease versus medication exposure. Of note when interpreting these
ﬁndings, two population-based health registries of data from infants
born tomothers with chronic inﬂammatory disease whowere either
exposed or not exposed to anti-TNF in utero found that birth defects
were slightly more common in those infants who were born to
mothers with chronic inﬂammatory disease regardless of whether
they were treated with anti-TNF agents and that no speciﬁc pattern
of defects could be found to suggest a common etiology (Bröms
et al., 2016).
A 2014 reviewof 105 articles on the use of anti-TNF therapy in pa-
tients with IBD and pregnancy found that anti-TNF agents were safe
during pregnancy, and the authors even recommended maintained
use and initiation of therapy with anti-TNF agents for patients who
were refractory to azathioprine, steroids, and 5-aminosalicylate
(Khan et al., 2014). Clowse (2010) looked at the effect on pregnancy
of inﬂiximab, adalimumab, and etanercept both combined and indi-
vidually compared with the general population and found no signiﬁ-
cant differences in the number of live-born infants, miscarriages,
elective terminations, or congenital abnormalities.
Treatment considerations for agents during
pregnancy and breastfeeding
Historically, the FDA categorizedmedications into ﬁve categories:
A, B, C, D, and X. Under the old FDA classiﬁcation system, biologic
agents were classiﬁed as a Pregnancy Category B: animal studies
Table 1
Summary of available data on biologic agents in pregnancy
Biologic
Agent
FDA
Approval
Mechanism of
Action
Structure Studies
Certolizumab
Cimzia
PsA TNF-alpha inhibition PEGylated Fab′ IgG fragment of
humanized monoclonal
antibody
Limited data:
- Multiple studies (cohorts, case control, case reports/series) of more than 300
pregnancies show no increased risk of miscarriage or congenital malformation;
however, no studies with control group available (Götestam Skorpen et al.,
2016).
- Low levels in cord blood, suggesting minimal active transplacental transport
(Förger et al., 2016)
Secukinumab
Cosentyx
PsO
PsA
IL-17 inhibition IgG1κmonoclonal antibody Extremely limited data:
- No human studies
- Studies in mice and monkeys show no embryofetal toxicity
Etanercept
Enbrel
PsO
PsA
TNF-alpha inhibition Fc Fragment of human
IgG fusion protein
Limited data:
- Multiple studies (cohorts, case controls, registry data, case reports/series)
of more than 300 exposed pregnancies show no difference in miscarriage or
congenital malformations compared with controls
(Götestam Skorpen et al., 2016).
Adalimumab
Humira
PsO
PsA
TNF-alpha inhibition IgG1 Fully human
monoclonal antibody
Limited data:
- Multiple studies (cohorts, case controls, registry data, case reports/series) of
more than 500 exposed pregnancies show no difference in miscarriage or
congenital malformations compared with controls
(Götestam Skorpen et al., 2016).
Inﬂiximab
Remicade
PsO
PsA
TNF-alpha inhibition IgG1 Mouse-human chimeric
monoclonal antibody
Limited data:
- Multiple studies (cohorts, case controls, registry data, case reports/series) of
more than 1000 exposed pregnancies show no difference in miscarriage or
congenital malformations compared with controls
(Götestam Skorpen et al., 2016).
Ustekinumab
Stelara
PsO
PsA
IL-12/23 inhibition IgG1κmonoclonal antibody Very limited data:
- Few case reports/case series and limited registry data
(Götestam Skorpen et al., 2016).
- No increased risk of congenital defects or miscarriages
(Götestam Skorpen et al., 2016).
- One case report of spontaneous abortion is reported for a patient with
other risk factors (Fotiadou et al., 2012).
Ixekizumab
Taltz
PsO IL-17A inhibition Humanized IgG4
monoclonal antibody
Extremely limited data:
- No human studies
- One study in monkeys shows no harmful effect on the fetus when the
medication was administered during the ﬁrst 20 weeks of gestation.
Medication administration from week 20 to birth showed an increase in
neonatal deaths. No effects on the infants’ immune system development or
maturation were noted at 6 months of age (Clarke et al., 2015).
Fab, antigen-binding fragment antibody; FDA, U.S. Food and Drug Administration; IgG, Immunoglobin G; IL, interleukin; PsA, psoriatic arthritis; PsO, psoriasis
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did not show an increased risk to the fetus, there are no adequate and
well-controlled trials in humans, and the beneﬁts of the drug may be
acceptable despite potential risks (FDA, 2014; 2016). When com-
pared with other psoriasis treatment options, biologic agents have
similar or better data available to address relative safety during preg-
nancy. It is worth nothing that methotrexate, which is sometimes
used in conjunction with biologic agents, is classiﬁed as Pregnancy
Category X and has been linked to spontaneous abortion when ad-
ministered in high doses.
In 2015, this ﬁve-letter system was changed due to concerns that
it was oversimpliﬁed and did not accurately assess risk. The new FDA
labeling requirement, the Pregnancy and Lactation Labeling Rule,
went into effect on June 30, 2015 and provides more detailed infor-
mation to healthcare providers in three categories: pregnancy, lacta-
tion, and females and males of reproductive potential. Under the
pregnancy category, speciﬁc clinical summaries, data, and risk sum-
maries are presented. Information about pregnancy registries is also
required as part of the new labeling. This information is available
under Sections 8.1 to 8.3, Special Populations, of the package insert
of medications (FDA).
Although data on treatment with speciﬁc biologic agents during
pregnancy has increased signiﬁcantly in the last decade, the use of bi-
ologic agents in pregnant patients with psoriasis is less studied com-
paredwith treatment in patientswith rheumatic disease or IBD. Thus,
few data are available on more psoriasis-speciﬁc medications such as
ustekinumab, secukinumab, and ixekizumab. A summary of available
data on individual biologic agents is listed in Table 1.
Most package inserts for medications warn against breastfeeding
while being treated with biologic agents, but recent data shows that
breastfeedingmay overall be safe for nursingmothers without signif-
icant risk to newborn babies. Low levels of TNF-alpha inhibitors can
be detected in breast milk (Gisbert and Chaparro, 2013). However,
because this milk is digested with gastric acid that is secreted by
the baby, protein degradation likely occurs and makes newborn
levels of anti-TNF agents very low (Clowse, 2010). Thus, many re-
searchers have asserted that there is very little to no risk to the
breastfed infant (Clowse, 2010). No speciﬁc data are available on
the safety of breastfeeding and use of other biologic agents such as
ixekizumab, ustekinumab, and secukinumab at this time.
Conclusions
Although no well-controlled trials have studied the effects of
treatment with biologic agents during pregnancy, the increasing
body of literature suggests that biologic agents can be used for the
treatment of psoriasis during pregnancy and breastfeeding. Current
recommendations for the treatment of patients with psoriasis during
pregnancy are as follows. First, anti-TNF-alpha agents should be con-
sidered over IL-12/23 and IL-17 inhibitors due to the increased avail-
ability of long-term data. Second, anti-TNF-alpha agents can be used
during the ﬁrst half of pregnancy. Thus, a pregnancy with early,
inadvertent exposure to anti-TNF alpha agents should not be consid-
ered at signiﬁcant risk. Third, longer-term use of anti-TNF alpha
agents during pregnancy can be considered depending on psoriasis
disease severity. Fourth, if treatment with biologic agents is required
throughout the pregnancy, use of certolizumab should be considered
because it does not cross the placenta in signiﬁcant amounts.
Etanercept may also be a reasonable alternative because its placental
transfer is less than adalimumab or inﬂiximab. Fifth, babies born to
mothers who are continually treated with biologic agents should
not be administered live vaccinations for 6 months after birth due
to the increased risk of infection. Inactive vaccinations can be admin-
istered in accordance with CDC-recommended guidelines. Sixth,
breastfeeding by mothers currently treated with anti-TNF alpha bio-
logic treatment regimens is generally considered safe due to themin-
imal amounts ofmedication that are present in breastmilk and infant
gastric digestion. Although actual data are primarily for anti-TNF
agents, this safety proﬁle is likely generalizable to the newer IL-12/
23 and IL-17 inhibitors as well. Seventh, cotreatment with metho-
trexate and biologic agent should be avoided. Eighth, psoriasis as a
disease is itself a risk factor for adverse pregnancy outcomes and per-
haps control of disease prior to and during pregnancy may optimize
maternal and fetal health.
Finally, adverse pregnancy outcomes should be reported to regis-
tries such as theOrganization of Teratology Information Specialists or
to manufacturer-sponsored pregnancy surveillance programs to in-
crease our understanding of the effects of treatment with biologic
agents during pregnancy and breastfeeding (Table 2).
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